Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The approval of sofosbuvir (SOF), a direct-acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). Methods: We assessed the sustained virological response (SVR) of SOF-based regimens in a real-world single-center setting for the treatment of chronic HCV genotype 1 (G1) patients. This was a retrospective review of chronic HCV G1 adult patients treated with a SOF-based regimen at Virginia Mason Medical Center between December 2013 and August 2015. Results: The cohort comprised 343 patients. Patients received SOF+ledipasvir (LDV) (n=155), SOF+simeprevir (SIM) (n=154), or SOF+peginterferon (PEG)+ribavirin (RBV) (n=34). Of the patients, 50.1% (n=172) had cirrhosis. The SVR rate was 92.2% for SOF/LDV, 87.0% for SOF/SIM, and 82.4% for SOF/PEG/RBV. Compared with the cirrhotic patients, the patients without cirrhosis had a higher SVR (96.8% vs 85.5%, p=0.01, SOF/LDV; 98.2% vs 80.6%, p=0.002, SOF/SIM; 86.4% vs 75.0%, p=0.41, SOF/PEG/RBV). In this study, prior treatment experience adversely affected the response rate in subjects treated with SOF/PEG/RBV. Conclusions: In this single-center, real-world setting, the treatment of chronic HCV G1 resulted in a high rate of SVR, especially in patients without cirrhosis.
Abstract
Background/Aims: The approval of sofosbuvir (SOF), a direct-acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). Methods: We assessed the sustained virological response (SVR) of SOF-based regimens in a real-world single-center setting for the treatment of chronic HCV genotype 1 (G1) patients. This was a retrospective review of chronic HCV G1 adult patients treated with a SOF-based regimen at Virginia Mason Medical Center between December 2013 and August 2015. Results: The cohort comprised 343 patients. Patients received SOF+ledipasvir (LDV) (n=155), SOF+simeprevir (SIM) (n=154), or SOF+peginterferon (PEG)+ribavirin (RBV) (n=34). Of the patients, 50.1% (n=172) had cirrhosis. The SVR rate was 92.2% for SOF/LDV, 87.0% for SOF/SIM, and 82.4% for SOF/PEG/RBV. Compared with the cirrhotic patients, the patients without cirrhosis had a higher SVR (96.8% vs 85.5%, p=0.01, SOF/LDV; 98.2% vs 80.6%, p=0.002, SOF/SIM; 86.4% vs 75.0%, p=0.41, SOF/PEG/RBV). In this study, prior treatment experience adversely affected the response rate in subjects treated with SOF/PEG/RBV. Conclusions: In this single-center, real-world setting, the treatment of chronic HCV G1 resulted in a high rate of SVR, especially in patients without cirrhosis.
참고문헌 (19)
- Szabó E, "Viral hepatitis: new data on hepatitis C infection", Pathol Oncol Res, 9, pp.215~221 (2003)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Fried MW, "Once-daily simeprevir (TMC435)with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study", Hepatology, 58, pp.1918~1929 (2013)
- Kowdley KV, "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial", Lancet, 381, pp.2100~2107 (2013)
- Lawitz E, "Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatmentnaive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2trial", Lancet, 383, pp.515~523 (2014)
- Terrault N, "Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir", sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study, 2016, pp.62, 256A~
- Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
- Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)
- Kwo P, "Simeprevir plus sofosbuvir (12and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study", Hepatology, 64, pp.370~380 (2016)
- Lawitz E, "Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)", Hepatology, 64, pp.360~369 (2016)
- Backus LI, "Effectiveness of sofosbuvir-based regimens in genotype 1 and 2hepatitis C virus infection in 4026 U.S. Veterans", Aliment Pharmacol Ther, 42, pp.559~573 (2015)
- Sulkowski MS, "Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in realworld patients with HCV genotype 1 infection", Gastroenterology, 150, pp.419~429 (2016)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- Conjeevaram HS, "Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1", Gastroenterology, 131, pp.470~477 (2006)
- Asselah T, "Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin", Liver Int, 30, pp.1259~1269 (2010)
- Kowdley KV, "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis", N Engl J Med, 370, pp.1879~1888 (2014)
- Nasrollah L, "Diabetes and hyperlipidemia compromise practical effectiveness of direct acting antiviral HCV therapy in minority populations", Gastroenterology, 148(4 Suppl 1), pp.S-1087~ (2015)
- Preveden T, "Chronic hepatitis C and alcohol abuse: the single center experience of Novi Sad - Serbia", Rev Recent Clin Trials, 11, pp.208~212 (2016)